

Subscribing organizations are encouraged to copy and distribute this table of contents for non-commercial purposes

## Early Career Research Awards



Development of inhibitors as research tools for carbohydrate-processing enzymes

**Tracey M. Gloster**

**913–928**



Synthesis of post-translationally modified proteins

**Sander van Kasteren**

**929–944**

## Biochemical Society Focused Meetings

### **Intrinsically Disordered Proteins**

University of York, U.K., 26–27 March 2012

**Edited by Jennifer Potts (York, U.K.) and Mike Williamson (Sheffield, U.K.).**

Intrinsically disordered proteins: administration not executive

**Mike P. Williamson and Jennifer R. Potts**

**945–949**

Bacterial in-cell NMR of human  $\alpha$ -synuclein: a disordered monomer by nature?

**Andres Binolfi, Francois-Xavier Theillet and Philipp Selenko**



**950–954**

Structural characterization of intrinsically disordered proteins by the combined use of NMR and SAXS

**Nathalie Sibille and Pau Bernadó**

**955–962**

Diverse functional manifestations of intrinsic structural disorder in molecular chaperones

**Denes Kovacs and Peter Tompa**

**963–968**

Regulation of protein phosphatase 1 by intrinsically disordered proteins

**Meng S. Choy, Rebecca Page and Wolfgang Peti**

**969–974**

Interplay between allostery and intrinsic disorder in an ensemble

**Hesam N. Motlagh, Jing Li, E. Brad Thompson and Vincent J. Hilser**

**975–980**

Cell cycle regulation by the intrinsically disordered proteins p21 and p27  
**Mi-Kyung Yoon, Diana M. Mitrea, Li Ou and Richard W. Kriwacki** 981–988

Residual dipolar couplings measured in unfolded proteins are sensitive to amino-acid-specific geometries as well as local conformational sampling  
**Jie-rong Huang, Martin Gentner, Navratna Vajpai, Stephan Grzesiek and Martin Blackledge** 989–994



### **Selected oral communications**

An intrinsically disordered protein, CP12: jack of all trades and master of the Calvin cycle  
**Brigitte Gontero and Stephen C. Maberly** 995–999

LEA proteins: IDPs with versatile functions in cellular dehydration tolerance  
**Dirk K. Hincha and Anja Thalhammer** 1000–1003

Mechanisms of small-molecule binding to intrinsically disordered proteins  
**Rémi Cuchillo and Julien Michel** 1004–1008

Native disorder mediates binding of dynein to NudE and dynactin  
**Elisar Barbar** 1009–1013

Using NMR chemical shifts to calculate the propensity for structural order and disorder in proteins  
**Kamil Tamiola and Frans A.A. Mulder** 1014–1020

Intrinsic disorder in proteins: a challenge for (un)structural biology met by ion mobility-mass spectrometry  
**Ewa Jurnecko, Faye Cruickshank, Massimiliano Porrini, Penka Nikolova, Iain D.G. Campuzano, Michael Morris and Perdita E. Barran** 1021–1026



Structures and interactions in ‘bottlebrush’ neurofilaments: the role of charged disordered proteins in forming hydrogel networks  
**Roy Beck, Joanna Deek and Cyrus R. Safinya** 1027–1031

Evolutionary selection for protein aggregation  
**Natalia Sanchez de Groot, Marc Torrent, Anna Villar-Piqué, Benjamin Lang, Salvador Ventura, Jörg Gsponer and M. Madan Babu** 1032–1037

---

### **LRRK2: Function and Dysfunction**

Royal Holloway, University of London, Egham, UK, 28–30 March 2012

**Edited by Patrick Lewis (University College London, U.K.) and Dario Alessi (Dundee, U.K.).**

---

Deciphering the function of leucine-rich repeat kinase 2 and targeting its dysfunction in disease  
**Patrick A. Lewis and Dario R. Alessi** 1039–1041

Genetic analysis of Parkinson’s disease-linked leucine-rich repeat kinase 2  
**Youren Tong and Jie Shen** 1042–1046

The synaptic function of LRRK2  
**Seongsoo Lee, Yuzuru Imai, Stephan Gehrke, Song Liu and Bingwei Lu** 1047–1051

Biochemical and functional characterization of the ROC domain of DAPK establishes a new paradigm of GTP regulation in ROCO proteins <b>Shani Bialik and Adi Kimchi</b>	1052–1057
Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease <b>Elisa Greggio</b>	1058–1062
The GTPase function of LRRK2 <b>Jean-Marc Taymans</b>	1063–1069
Cellular effects of LRRK2 mutations <b>Mark R. Cookson</b>	1070–1073
LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease <b>Yulan Xiong, Valina L. Dawson and Ted M. Dawson</b>	1074–1079
<b>Selected oral communications</b>	
Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models <b>Maximilian Sloan, Javier Alegre-Abarrategui and Richard Wade-Martins</b>	1080–1085
Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations <b>Ryan D. Mills, Terrence D. Mulhern, Heung-Chin Cheng and Janetta G. Culvenor</b>	1086–1089
MASL1: a neglected ROCO protein <b>Sybille Dihanich</b>	1090–1094
Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions? <b>Laura Civiero and Luigi Bubacco</b>	1095–1101
Phosphorylation of LRRK2: from kinase to substrate <b>Evy Lobbestael, Veerle Baekelandt and Jean-Marc Taymans</b>	1102–1110
Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2 <b>Elisa Belluzzi, Elisa Greggio and Giovanni Piccoli</b>	1111–1116
LRRK2 and vesicle trafficking <b>Giovanna Sanna, Maria Grazia Del Giudice, Claudia Crosio and Ciro Iaccarino</b>	1117–1122
The importance of Wnt signalling for neurodegeneration in Parkinson's disease <b>Daniel C. Berwick and Kirsten Harvey</b>	1123–1128
Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease <b>José M. Bravo-San Pedro, Rubén Gómez-Sánchez, Mireia Niso-Santano, Elisa Pizarro-Estrella, Rosa A. González-Polo and José M. Fuentes</b>	1129–1133
An emerging role for LRRK2 in the immune system <b>Nicolas Dzamko and Glenda M. Halliday</b>	1134–1139
A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling <b>Patricia Gómez-Suaga, Grant C. Churchill, Sandip Patel and Sabine Hilfiker</b>	1140–1146

LRRK2 and autophagy: a common pathway for disease

**Claudia Manzoni**

**1147–1151**

Cellular reprogramming: a new approach to modelling Parkinson's disease

**Elizabeth M. Hartfield, Hugo J.R. Fernandes, Jane Vowles, Sally A. Cowley and Richard Wade-Martins**

**1152–1157**

Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology

**Jing Zhao, Spencer B. Hermanson, Coby B. Carlson, Steven M. Riddle, Kurt W. Vogel, Kun Bi and R. Jeremy Nichols**

**1158–1162**